Summary: In an 8-week trial in overweight and obese adults, a standardized hibiscus-inulin shot produced small reductions in composite lipid-glucose indices versus placebo, with no change in blood pressure; the authors stress these reflect analytical responsiveness rather than proven clinical benefit.
PICO Summary
| Element | Detail |
|---|---|
| Population | 100 adults aged 18–50 with BMI ≥25; randomised, double-blind, placebo-controlled trial, Mexico. |
| Intervention | Daily 60 mL LC-MS-standardised hibiscus-inulin shot for 8 weeks (n=50). |
| Comparison | Sensory-matched placebo beverage (n=50). |
| Outcome | Adjusted 8-week differences versus placebo were -0.09 for the atherogenic index of plasma (95% CI -0.15 to -0.03; p=0.004) and -0.14 for the triglyceride-glucose index (95% CI -0.26 to -0.03; p=0.020). Mean arterial pressure and pulse pressure did not differ. Effects were larger in higher-baseline-risk participants. The authors note no minimal clinically important difference exists for these indices over short durations, so results reflect analytical responsiveness rather than clinical benefit. |
Hibiscus-inulin shot in overweight adults
RCT · overweight/obesity · 8 weeks
Small, statistically significant reductions in surrogate lipid-glucose indices versus placebo, with no blood-pressure effect. Authors stress these reflect analytical responsiveness, not proven clinical benefit.
Expert Commentary
This is a carefully reported trial that is unusually honest about the limits of its own endpoints, and that honesty should anchor interpretation. The intervention is rational, since hibiscus polyphenols and the prebiotic fibre inulin plausibly nudge lipid and glucose handling, and the standardised formulation is a methodological strength that aids reproducibility. The reductions in the atherogenic and triglyceride-glucose indices were statistically significant, but they are composite calculated ratios rather than hard outcomes, and crucially the investigators themselves caution that no minimal clinically important difference has been established for these indices over eight weeks, so the changes demonstrate that the indices can move rather than that patients benefit. The absence of any blood-pressure effect and the short duration reinforce a measured reading. Can I use this with my patients? Only lightly. For a patient who enjoys a hibiscus-and-fibre drink as part of a healthier pattern, it is harmless and may modestly favour their lipid-glucose profile, but I would not present it as a treatment, would be clear the trial showed surrogate-index movement rather than clinical benefit, and would keep diet quality, weight, and proven therapies central.
References
Mendivil EJ, Rivera-Iñiguez I, Arellano-Gómez LP, et al. Standardized hibiscus-inulin shot lowers lipid-glucose indices in adults with overweight and obesity: 8-week randomized trial. Nutrients. 2025;17(22):3556. doi:10.3390/nu17223556